Clinical Trials

Histology-Agnostic Drug Development — Considering Issues Beyond the Tissie

OccamPoint

*Presagia AI (OccamPoint Partner member)The landmark approvals of pembrolizumab for the treatment of patients whose tumors have high microsatellite instability and larotrectinib and entrectinib for those harbouring NTRK fusions, have marked the beginning of the era of histology-agnostic drug development in oncology.  However, the path to regulatory approval in the space remains complex due to the potential for heterogeneous histologies and…

Read More